EA201401225A1 - F-меченые аналоги фолата/антифолата - Google Patents

F-меченые аналоги фолата/антифолата

Info

Publication number
EA201401225A1
EA201401225A1 EA201401225A EA201401225A EA201401225A1 EA 201401225 A1 EA201401225 A1 EA 201401225A1 EA 201401225 A EA201401225 A EA 201401225A EA 201401225 A EA201401225 A EA 201401225A EA 201401225 A1 EA201401225 A1 EA 201401225A1
Authority
EA
Eurasian Patent Office
Prior art keywords
folate
antipholate
well
tagged
analogs
Prior art date
Application number
EA201401225A
Other languages
English (en)
Inventor
Роже Шибли
Рудольф Мозер
Кристина Магдалена Мюллер
Зимон Менсах Аметамей
Томас Бетцель
Виола Грён
Original Assignee
Мерк Э Сие
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Э Сие filed Critical Мерк Э Сие
Publication of EA201401225A1 publication Critical patent/EA201401225A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение является направленным на новые аналоговые радиофармацевтические лекарственные средстваF-фолата/антифолата, где фенильная группа в структуре фолата была заменена наF-гетероцикл, их исходные вещества, способ их получения, а также их использование в диагностике клетки или популяции клеток, экспрессирующих фолат-рецептор и мониторинге рака и аутоиммунных заболеваний, а также их лечении.
EA201401225A 2012-05-08 2013-05-08 F-меченые аналоги фолата/антифолата EA201401225A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12167126 2012-05-08
PCT/EP2013/059584 WO2013167653A1 (en) 2012-05-08 2013-05-08 18f-labelled folate/antifolate analogues

Publications (1)

Publication Number Publication Date
EA201401225A1 true EA201401225A1 (ru) 2015-04-30

Family

ID=48407549

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201401225A EA201401225A1 (ru) 2012-05-08 2013-05-08 F-меченые аналоги фолата/антифолата

Country Status (18)

Country Link
US (1) US10357576B2 (ru)
EP (1) EP2864329B1 (ru)
JP (1) JP6198814B2 (ru)
KR (1) KR102116000B1 (ru)
CN (1) CN104379585B (ru)
AU (1) AU2013258027B2 (ru)
CA (1) CA2870124C (ru)
DK (1) DK2864329T3 (ru)
EA (1) EA201401225A1 (ru)
ES (1) ES2703627T3 (ru)
HK (1) HK1202548A1 (ru)
IL (1) IL235476B (ru)
PL (1) PL2864329T3 (ru)
PT (1) PT2864329T (ru)
SG (1) SG11201406481TA (ru)
TR (1) TR201819802T4 (ru)
WO (1) WO2013167653A1 (ru)
ZA (1) ZA201407266B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101646577B1 (ko) * 2014-08-14 2016-08-09 원광대학교산학협력단 엽산수용체 표적용 화합물 또는 이의 약학적으로 허용가능한 염과, 이를 유효성분으로 포함하는 암 예방, 진단 또는 치료용 조성물
WO2018172243A1 (en) * 2017-03-20 2018-09-27 Merck Patent Gmbh Isomerically pure 18f-labelled tetrahydrofolates
EP3671511B1 (en) 2018-12-19 2022-07-06 Rohde & Schwarz GmbH & Co. KG Communication system and method
DE102019110904B4 (de) * 2019-04-26 2022-01-20 Helmholtz-Zentrum Dresden - Rossendorf E. V. N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
EP4175719A1 (en) 2020-07-02 2023-05-10 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070276231A1 (en) 2004-12-23 2007-11-29 Low Philip S Positron Emission Tomography Imaging Method
JP4503039B2 (ja) 2006-04-27 2010-07-14 三洋電機株式会社 回路装置
EP2109466B1 (en) 2007-02-07 2014-11-12 Purdue Research Foundation Positron emission tomography imaging method
JP5595903B2 (ja) 2007-04-11 2014-09-24 メルク エ カンパニー １８ｆ標識葉酸
EA200901344A1 (ru) 2007-04-11 2010-04-30 Мерк Эпрова Аг Фолат-конъюгаты и соответствующие комплексы хелатов металлов для применения для диагностической визуализации и лучевой терапии
ES2449774T3 (es) 2007-04-11 2014-03-21 Merck & Cie Un método para la preparación de folatos marcados con 18F
EA200901346A1 (ru) * 2007-04-11 2010-04-30 Мерк Эпрова Аг F-меченые фолаты
EA201100598A1 (ru) 2008-10-10 2011-12-30 Мерк Э Сие F-меченые фолаты в качестве рет радиоактивных индикаторов

Also Published As

Publication number Publication date
DK2864329T3 (en) 2019-01-21
EP2864329A1 (en) 2015-04-29
CA2870124C (en) 2021-02-16
AU2013258027A1 (en) 2014-11-13
WO2013167653A1 (en) 2013-11-14
ZA201407266B (en) 2016-09-28
KR20150010970A (ko) 2015-01-29
KR102116000B1 (ko) 2020-05-29
US20150125390A1 (en) 2015-05-07
CA2870124A1 (en) 2013-11-14
SG11201406481TA (en) 2014-11-27
EP2864329B1 (en) 2018-09-26
CN104379585B (zh) 2018-07-06
CN104379585A (zh) 2015-02-25
ES2703627T3 (es) 2019-03-11
AU2013258027B2 (en) 2017-11-30
JP2015516405A (ja) 2015-06-11
IL235476B (en) 2019-09-26
IL235476A0 (en) 2014-12-31
PL2864329T3 (pl) 2019-03-29
HK1202548A1 (en) 2015-10-02
PT2864329T (pt) 2019-01-10
JP6198814B2 (ja) 2017-09-20
US10357576B2 (en) 2019-07-23
TR201819802T4 (tr) 2019-01-21

Similar Documents

Publication Publication Date Title
EA201401225A1 (ru) F-меченые аналоги фолата/антифолата
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201300558A1 (ru) Соединения и способы для купирования боли
EA201490546A1 (ru) Замещенные аннелированные пиримидины и их применение
MX2014016014A (es) Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon.
EA201591087A1 (ru) Новые производные бензимидазола в качестве антагонистов рецептора ep4
CL2014003110A1 (es) Anticuerpo anti-fcrn; secuencias que lo codifican; vector; célula huésped; proceso de producción; composición farmacéutica que lo comprende; uso para el tratamiento de enfermedad autoinmune; y ensayo para probar la capacidad de un anticuerpo para bloquear la actividad de fcrn humano.
EA201491973A1 (ru) Новые соединения
EA201991484A1 (ru) Лекарственные формы энзалутамида
SMT201700021B (it) Metodi per il trattamento di malattie autoimmuni con antagonisti del dll4
EA201590868A1 (ru) Противовирусные соединения
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EA202190619A1 (ru) Противовирусные соединения
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
EA201790963A1 (ru) Противовирусные соединения
AR092188A1 (es) ANTICUERPOS HUMANOS PARA GFRa3 Y METODOS PARA SU USO
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
UY33202A (es) Proteínas de unión a cd127
ES2446643R1 (es) Composiciones farmacéuticas combinadas y su uso para preparar un medicamento destinado al tratamiento del vértigo, la cinetosis y la distonía vegetativa-vascular
EA201590359A1 (ru) Лечение ревматоидного артрита
EA201590797A1 (ru) Препараты с модифицированным высвобождением опрозомиба
EA201391440A1 (ru) Производные пиразолопиримидина
CY1117968T1 (el) Θεραπευτικη χρηση της πρωτεϊνης β2-μικροσφαιρινη